MX348113B - Genes ospa quimericos, proteinas, y metodos para usar los mismos. - Google Patents

Genes ospa quimericos, proteinas, y metodos para usar los mismos.

Info

Publication number
MX348113B
MX348113B MX2012013261A MX2012013261A MX348113B MX 348113 B MX348113 B MX 348113B MX 2012013261 A MX2012013261 A MX 2012013261A MX 2012013261 A MX2012013261 A MX 2012013261A MX 348113 B MX348113 B MX 348113B
Authority
MX
Mexico
Prior art keywords
chimeric ospa
chimeric
proteins
methods
ospa
Prior art date
Application number
MX2012013261A
Other languages
English (en)
Spanish (es)
Other versions
MX2012013261A (es
Inventor
O'rourke Maria
Schwendinger Michael
A Crowe Brian
Livey Ian
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX2012013261A publication Critical patent/MX2012013261A/es
Publication of MX348113B publication Critical patent/MX348113B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2012013261A 2010-05-14 2011-05-13 Genes ospa quimericos, proteinas, y metodos para usar los mismos. MX348113B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33490110P 2010-05-14 2010-05-14
PCT/US2011/036525 WO2011143617A1 (en) 2010-05-14 2011-05-13 Chimeric ospa genes, proteins, and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2012013261A MX2012013261A (es) 2013-04-19
MX348113B true MX348113B (es) 2017-05-29

Family

ID=44121257

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017006896A MX375965B (es) 2010-05-14 2011-05-13 Genes ospa quimericos, proteinas, y metodos para usar los mismos.
MX2012013264A MX340739B (es) 2010-05-14 2011-05-13 Quimeras ospa y su uso en vacunas.
MX2012013261A MX348113B (es) 2010-05-14 2011-05-13 Genes ospa quimericos, proteinas, y metodos para usar los mismos.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2017006896A MX375965B (es) 2010-05-14 2011-05-13 Genes ospa quimericos, proteinas, y metodos para usar los mismos.
MX2012013264A MX340739B (es) 2010-05-14 2011-05-13 Quimeras ospa y su uso en vacunas.

Country Status (13)

Country Link
US (6) US8623375B2 (OSRAM)
EP (4) EP3705133B1 (OSRAM)
JP (6) JP6030052B2 (OSRAM)
KR (7) KR20130062954A (OSRAM)
CN (3) CN103118701B (OSRAM)
AU (2) AU2011252844B2 (OSRAM)
BR (2) BR112012027315B1 (OSRAM)
CA (2) CA2798331C (OSRAM)
MX (3) MX375965B (OSRAM)
PL (2) PL2569008T3 (OSRAM)
RU (2) RU2636455C2 (OSRAM)
SI (2) SI2569009T1 (OSRAM)
WO (2) WO2011143617A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012027315B1 (pt) * 2010-05-14 2021-08-17 Baxalta Incorporated Polipeptídeo, composição, molécula de ácido nucleico, vetor, microrganismo transgênico, processo de produção de um polipeptídeo, vacina combinada, e, uso de uma composição ou de uma vacina combinada
AU2011316955B2 (en) 2010-10-20 2016-12-01 Playspan Inc. Flexible monetization service apparatuses, methods and systems
US10438176B2 (en) 2011-07-17 2019-10-08 Visa International Service Association Multiple merchant payment processor platform apparatuses, methods and systems
US10318941B2 (en) 2011-12-13 2019-06-11 Visa International Service Association Payment platform interface widget generation apparatuses, methods and systems
WO2013090611A2 (en) * 2011-12-13 2013-06-20 Visa International Service Association Dynamic widget generator apparatuses, methods and systems
US8986704B2 (en) * 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
KR20200068756A (ko) * 2012-07-27 2020-06-15 박스알타 인코퍼레이티드 키메라 ospa 분자를 포함하는 조성물 및 이의 사용 방법
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
KR102267292B1 (ko) * 2013-03-15 2021-06-21 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 미토콘드리아 유래의 펩티드 ｍｏｔｓ3에 의해 조절되는 물질대사 및 세포 생존
WO2015041710A1 (en) * 2013-09-23 2015-03-26 Ventria Bioscience, Inc. Ospa fusion protein for vaccination against lyme disease
AU2015205520B2 (en) * 2014-01-09 2017-06-29 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
CZ2014320A3 (cs) * 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
CA2958018A1 (en) 2014-08-11 2016-02-18 University Of Massachusetts Anti-ospa antibodies and methods of use
US11216468B2 (en) 2015-02-08 2022-01-04 Visa International Service Association Converged merchant processing apparatuses, methods and systems
KR20200047751A (ko) * 2015-08-14 2020-05-07 텔레호낙티에볼라게트 엘엠 에릭슨(피유비엘) 패킷 데이터 네트워크 연결을 관리하기 위한 노드 및 방법
CN110167584B (zh) * 2016-11-07 2024-06-07 威斯塔解剖学和生物学研究所 用于针对莱姆病的dna抗体构建体
CA3059817A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
WO2019195276A1 (en) * 2018-04-03 2019-10-10 Sanofi Antigenic ospa polypeptides
JP7614842B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性エプスタインバーウイルスポリペプチド
CN112512564A (zh) 2018-04-03 2021-03-16 赛诺菲 铁蛋白蛋白
WO2019195291A1 (en) 2018-04-03 2019-10-10 Sanofi Antigenic respiratory syncytial virus polypeptides
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111196842A (zh) * 2020-01-09 2020-05-26 济南大学 一种外膜转运通道蛋白的非跨膜结构域的表达纯化方法
CA3174892A1 (en) * 2020-04-09 2021-10-14 Valneva Austria Gmbh Compositions comprising three ospa fusion proteins for medical use
EP4146253A1 (en) 2020-04-09 2023-03-15 Valneva Austria GmbH Improvements in vaccine formulations for medical use
WO2022133233A2 (en) 2020-12-17 2022-06-23 Idexx Laboratories, Inc. Rocky mountain spotted fever detection and treatment
WO2022261050A1 (en) * 2021-06-07 2022-12-15 The University Of Massachusetts Apparatus and method for continuous production of rna
EP4490042A1 (en) 2022-03-08 2025-01-15 Equashield Medical Ltd. Fluid transfer station in a robotic pharmaceutical preparation system
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4830885A (en) 1987-06-08 1989-05-16 Allied-Signal Inc. Chlorine-resistant semipermeable membranes
US6143872A (en) 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US7094391B1 (en) 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0536335A4 (en) * 1990-06-15 1993-07-14 Yale University Compositions and methods for the prevention and diagnosis of lyme disease
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
WO1992014488A1 (en) 1991-02-15 1992-09-03 Uab Research Foundation Structural gene of pneumococcal protein
AU666326B2 (en) * 1991-08-15 1996-02-08 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Osp A proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
WO1995012676A1 (en) * 1993-11-01 1995-05-11 Associated Universities, Inc. Chimeric proteins comprising borrelia polypeptides: uses therefor
AU724716B2 (en) 1996-02-12 2000-09-28 Ml Laboratories Plc Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
DK1012181T3 (da) * 1997-06-30 2007-01-02 Univ Tulane Overfladeantigener og proteiner, der er nyttige i præparater til diagnose og forebyggelse af Lymes sygdom
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
GB9811219D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
AU2001281145A1 (en) 2000-08-18 2002-03-04 Brookhaven Sciences Associates, Llc Recombinant constructs of borrelia burgdorferi
ES2298249T3 (es) 2000-08-18 2008-05-16 Research Foundation Of State University Of New York Ospa modificada de borrelia burgdorferi.
EP1939294A1 (en) * 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
CN101195649A (zh) 2003-04-02 2008-06-11 美国政府健康及人类服务部 含胆固醇的化合物以及其用作针对伯氏疏螺旋体(Borrelia burgdorferi)的免疫原的应用
US20070253964A1 (en) * 2003-04-16 2007-11-01 Zlotnick Gary W Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
ES2343255T3 (es) * 2004-03-24 2010-07-27 MERCK SHARP & DOHME CORP. Expresion optimizada del vph 52 l1 en levadura.
US8821893B2 (en) 2004-07-02 2014-09-02 Bio Peptides, Corp. Oral vaccine for Borrelia
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US7794727B2 (en) 2005-11-29 2010-09-14 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen
RU2008126239A (ru) * 2005-11-29 2010-01-10 Вирджиния Коммонвелт Юниверсити (Us) Поливалентный химерный вакциноген и диагностический антиген ospc
AU2007295927A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
WO2008101667A1 (en) 2007-02-22 2008-08-28 Baxter International Inc. Method of purification of hydrophobic proteins
EP2687228B1 (en) * 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
ES2685435T3 (es) * 2008-01-11 2018-10-09 Inovio Pharmaceuticals, Inc. Nuevas vacunas frente a múltiples subtipos del virus del dengue
WO2009131665A1 (en) 2008-04-22 2009-10-29 Research Foundation Of State University Of New York Borrelia burgdorferi cell envelope protein array
WO2009135118A2 (en) 2008-05-02 2009-11-05 Virginia Commonwealth University Lyme disease vaccine
BR112012027315B1 (pt) 2010-05-14 2021-08-17 Baxalta Incorporated Polipeptídeo, composição, molécula de ácido nucleico, vetor, microrganismo transgênico, processo de produção de um polipeptídeo, vacina combinada, e, uso de uma composição ou de uma vacina combinada
KR20200068756A (ko) * 2012-07-27 2020-06-15 박스알타 인코퍼레이티드 키메라 ospa 분자를 포함하는 조성물 및 이의 사용 방법

Also Published As

Publication number Publication date
US20180296656A1 (en) 2018-10-18
CA2798331A1 (en) 2011-11-17
RU2017138652A3 (OSRAM) 2021-03-15
PL2569008T3 (pl) 2021-04-19
SI2569009T1 (sl) 2020-02-28
RU2012153972A (ru) 2014-06-20
JP6227407B2 (ja) 2017-11-08
US9303073B2 (en) 2016-04-05
BR112012029058A2 (pt) 2020-06-23
EP2569008A1 (en) 2013-03-20
US20110293652A1 (en) 2011-12-01
AU2011252844B2 (en) 2014-07-03
KR20130062954A (ko) 2013-06-13
WO2011143617A1 (en) 2011-11-17
EP3705133A2 (en) 2020-09-09
MX375965B (es) 2025-03-07
CN107641151B (zh) 2021-10-01
CA2799181C (en) 2023-10-24
KR102130584B1 (ko) 2020-07-07
CN103108652B (zh) 2016-05-11
US11305000B2 (en) 2022-04-19
CA2798331C (en) 2022-03-15
CN107641151A (zh) 2018-01-30
JP2016171816A (ja) 2016-09-29
US20140141029A1 (en) 2014-05-22
JP6965417B2 (ja) 2021-11-10
KR20130133120A (ko) 2013-12-06
US8623376B2 (en) 2014-01-07
KR102222869B1 (ko) 2021-03-04
BR112012027315B1 (pt) 2021-08-17
JP2018150386A (ja) 2018-09-27
CN103108652A (zh) 2013-05-15
KR20180082633A (ko) 2018-07-18
WO2011143623A1 (en) 2011-11-17
KR20200024354A (ko) 2020-03-06
MX340739B (es) 2016-07-22
BR112012029058B1 (pt) 2022-03-29
CA2799181A1 (en) 2011-11-17
US9334311B2 (en) 2016-05-10
AU2011252850B2 (en) 2016-03-17
JP2020178719A (ja) 2020-11-05
JP2013529077A (ja) 2013-07-18
JP2013529078A (ja) 2013-07-18
SI2569008T1 (sl) 2020-02-28
US20140141030A1 (en) 2014-05-22
PL2569009T3 (pl) 2020-06-15
RU2017138652A (ru) 2019-02-11
US9895434B2 (en) 2018-02-20
RU2012153752A (ru) 2014-06-20
KR20200084062A (ko) 2020-07-09
RU2583289C2 (ru) 2016-05-10
KR20190027955A (ko) 2019-03-15
EP2569008B1 (en) 2019-12-25
AU2011252844A1 (en) 2012-11-29
MX2012013264A (es) 2014-12-05
US20160235830A1 (en) 2016-08-18
CN103118701A (zh) 2013-05-22
AU2011252850A1 (en) 2012-11-29
EP3650041A1 (en) 2020-05-13
KR20180031814A (ko) 2018-03-28
KR102085465B1 (ko) 2020-03-05
EP2569009B1 (en) 2019-10-09
RU2636455C2 (ru) 2017-11-23
EP3705133A3 (en) 2021-01-06
EP3705133B1 (en) 2024-06-26
JP6030052B2 (ja) 2016-11-24
BR112012027315A8 (pt) 2020-09-01
BR112012027315A2 (pt) 2016-11-16
KR102230562B1 (ko) 2021-03-22
CN103118701B (zh) 2017-10-24
US20120020973A1 (en) 2012-01-26
MX2012013261A (es) 2013-04-19
US8623375B2 (en) 2014-01-07
EP2569009A1 (en) 2013-03-20
JP2016168057A (ja) 2016-09-23

Similar Documents

Publication Publication Date Title
MX348113B (es) Genes ospa quimericos, proteinas, y metodos para usar los mismos.
WO2014018274A8 (en) Compositions comprising chimeric ospa molecules and methods of use thereof
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
WO2012027379A3 (en) Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
IL180565A0 (en) An improved stopcock for administering medicaments into the patient's body
EP2958486A4 (en) DEVICE FOR ENABLING PATIENT SICKNESS TESTS AND TREATMENT INDIVIDUAL MANAGEMENT, AND SYSTEM WITH THE DEVICE FOR MANAGING HEALTH CARE FOR A PATIENT
MX2013007657A (es) Oligodesoxinucleotidos inmunoestimulantes.
IN2015DN03219A (OSRAM)
MX2020012426A (es) Anticuerpos anti-cd38.
MX340822B (es) Formulaciones para suministro oral de adsorbentes en el intestino.
IN2012DN06309A (OSRAM)
IL232325A0 (en) 18-methyl-7,6-methylene-3-oxo-17-paragan-4-en-21, 17b-carbolactones, pharmaceutical preparations containing these compounds and their use for the treatment of endometrial disease
MX2013013800A (es) Oligodesoxinucleotidos inmunoestimuladores.
MX2013013801A (es) Oligodesoxinucleotidos inmunoestimuladores.
EP2811832A4 (en) USE OF LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH MORBUS CROHN AFTER FAILED PREVIOUS ANTI-TNF THERAPY
WO2014079807A3 (de) Trokarvorrichtung und deren verwendung
EP3001813A4 (en) Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging
FR2928149B1 (fr) Composes derives d'azetidines, leur preparation et leur application en therapeutique
EP2925352A4 (en) HONESTICAL INVASIN FOR IMMUNIZATION, DIAGNOSIS AND CELL RELEASE
EP2271267A4 (en) MEDICAL DEVICE FOR THE PERI-OPERATIVE DELIVERY OF LIQUIDS AND METHOD FOR THE APPLICATION THEREOF
EP2528939A4 (en) RECOMBINANT PROTEINS FOR USE IN VACCINES, ANTIBODIES TO THESE PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES THEREWITH
GB201121914D0 (en) Method for patient selection
WO2013158818A3 (en) Vaccines and methods to treat lyme disease in dogs
EP2554198A4 (en) LIQUID DRUG DELIVERY DEVICE FOR ENDOSCOPIC SURGERY, MEDICAL CONTROL DEVICE FOR LIQUID MEDICINE, AND LIQUID DRUG DELIVERY DEVICE FOR ENDOSCOPIC SURGERY COMPRISING THE SAME
CY1111361T1 (el) Νεα προσδεματα συναγωνιστες των υποδοχεων rar, χρηση στην ανθρωπινη ιατρικη καθως και στην κοσμετολογια

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BAXALTA INCORPORATED

FG Grant or registration